Tag: 6

PALM BEACH, Fla., June 18, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The market for abuse-deterrent opioids is still developing, but it's estimated that replacing extended-release opioids with abuse-deterrent formulations could lead to significant cost savings and a reduction in abuse-related medical events. While specific revenue figures for the abuse-deterrent opioid market are not readily available, the potential impact on the broader opioid market is substantial. One such report from Roots Analysis, however, did project revenues, saying: “The abuse deterrent formulations market is estimated to grow from USD 25.7 million in 2024 to reach USD 39.8 million in 2025 and USD 54.8 million by 2030, representing a higher CAGR of 6.6% during the forecast period. Although the healthcare industry relies on patient to take medications responsibly, in 2017, close to 18 million individuals were reported to have misused prescription drugs, in the US. In fact, data from a National Survey on Drug Use and Health conducted in the same year, showed that an estimated 2 million Americans misused prescription pain relievers for the first time in the previous year. Moreover, the same study reported 1.5 million people abusing tranquilizers, over 1 million abusing prescription stimulants and more than 270,000 abusing sedatives, for the first time, in the same time period. Owing to a rapid onset of medicinal effect, which offers immediate relief (with high efficacy), opioids are still considered to be one of the most widely used pharmacological interventions for pain management. However, these drugs are known to induce a euphoric state upon consumption, often causing patients to abuse them; increased recreational use of opioids is known to lead to addiction. Moreover, over-prescription of such medicinal products, which promotes their misuse, is considered as one of the root causes of the opioid crisis (increasing number of deaths involving misuse and addiction to opioids), in the US. According to the Centers for Disease Control and Prevention (CDC), more than 72,000 overdose-related deaths were reported in 2017, of which close to 50,000 involved the use of an opioid.”   Active healthcare/tech companies active in the markets include: Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), Pfizer Inc. (NYSE: PFE), Collegium Pharmaceutical, Inc. (NASDAQ: COLL), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Emergent BioSolutions Inc. (NYSE: EBS).

CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to <16. Both non-ambulatory and ambulatory participants may qualify for the study. Participants will be randomized 2:1 to receive omaveloxolone or placebo once a day for 52 weeks before having the opportunity to move into the open-label extension (OLE). Currently, omaveloxolone is commercialized under the brand name SKYCLARYS^® in over 40 countries, including in the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.

ProVen VCT plc
ProVen Growth and Income VCT plc
Publication of Supplementary Prospectus

BORDEAUX, France, 18 juin 2025 (GLOBE NEWSWIRE) -- Financière Immobilière Bordelaise (410 312 110 RCS Bordeaux) (la « Société »), société holding du groupe éponyme spécialisé dans l’acquisition, la valorisation et la promotion d’actifs immobiliers (le « Groupe »), et émettrice d’obligations au titre d’un placement privé pour un montant nominal de 108 millions d’euros (ISIN FR0013479722) admises à la négociation sur Euronext Access (les « Obligations Euro PP »), annonce faire l’objet d’une procédure de redressement judiciaire ouverte, à sa demande, le 15 février 2023 par le Tribunal de commerce de Bordeaux.